Please wait while we load the requested 10-K report or click the link below:
FOR IMMEDIATE RELEASE
For investor inquiries:
John Mills, ICR
for Alimera Sciences
For press inquiries:
Katie Brazel, Fleishman-Hillard
for Alimera Sciences
ALIMERA SCIENCES REPORTS FOURTH QUARTER 2011 FINANCIAL RESULTS
ILUVIEN® expected to be first sustained release pharmaceutical in the
European Union (EU) to treat diabetic macular edema (DME)
Alimera believes marketing authorizations for ILUVIEN® will be received from
seven EU countries before the end of the First Quarter 2012
Cash, Cash Equivalents and Investments at December 31, 2011
Totaled $33.6 Million
Alimera Will Host a Conference Call at 4:30 P.M. ET Today
ATLANTA, GA March 8, 2012 Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter ended December 31, 2011.
Last week we announced the positive outcome of the Decentralized Procedure for ILUVIEN® in Europe, indicating that ILUVIEN is approvable, in the seven European countries in which we filed, for the treatment of chronic diabetic macular edema, said Dan Myers, Alimeras president and chief executive officer. We now are focused on the national phase of the process, during which labeling in each countrys local language is finalized. We expect to receive marketing authorization in each country by the end of the first quarter.
The International Diabetes Federation estimates that 19.1 million people are currently living with diabetes in the seven countries in which Alimera filed for marketing authorization (Austria, France, Germany, Italy, Portugal, Spain and the United Kingdom). Of these, Alimera estimates that 1.1 million people suffer from diabetic macular edema (DME).
I would like to reiterate that this is not only a positive achievement for Alimera, but an exciting development for the many patients in Europe suffering from this debilitating disease, said Mr. Myers. We are now working to ensure that ILUVIEN is made available to patients as soon as possible, which we expect to be by the end of 2012.
The following information was filed by Alimera Sciences Inc (ALIM) on Thursday, March 8, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alimera Sciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alimera Sciences Inc.